University of Illinois advances multivalent ETEC vaccine designed to target both toxins and adhesins

[University of Illinois Urbana-Champaign](https://app.allsci.com/organization/ASC-OH-0000000000003-1.0-1764853177) has received a [USD 1.12 million NIAID R01 grant](https://reporter.nih.gov/project-details/11333782) to advance MecVax, a multivalent subunit vaccine candidate targeting enterotoxigenic *Escherichia coli* (ETEC) — the leading bacterial cause of travelers' diarrhea and a top contributor to diarrheal mortality in children under five in low- and middle-income countries. With no licensed ETEC vaccine currently available, the award reflects sustained NIH interest in closing a long-standing gap in enteric disease prevention. ETEC causes an estimated 220 million diarrheal episodes annually and approximately 100,000 deaths, disproportionately affecting young children in lower-income settings where the pathogen also contributes to stunting and impaired cognitive development. MecVax is designed to address the antigenic diversity of ETEC by [simultaneously targeting both major toxins](https://app.allsci.com/article/ASC-PB-0000239184303-1.0-1731082310) — heat-labile toxin (LT) and heat-stable toxin (STa) — alongside seven key colonization factor adhesins (CFA/I, CS1–CS6). Because strains producing LT and/or STa account for all ETEC diarrhea cases, and strains expressing CFA/I or CS1–CS6 cause more than 66% of clinical cases, the combined antitoxin and anti-adhesin approach is intended to deliver broader coverage than single-antigen strategies. Preclinical data indicate MecVax induces protective immune responses against ETEC adherence and enterotoxicity. The fourth-year R01 award, administered through NIAID under funding opportunity RFA-AI-22-037, supports an academic-industry consortium. Partners include Johns Hopkins University and Advanced Bioscience Laboratories, with associated contract manufacturing organizations. The current funding period runs through May 2027, with the overall project extending to May 2028. Work under this award focuses on vaccine formulation optimization, upstream and downstream manufacturing process development, analytical method validation, master cell bank production, and preparation of a pre-IND application to the US FDA — milestones that would position MecVax for formal clinical entry. Principal investigator Weiping Zhang leads the effort from UIUC's College of Veterinary Medicine. The ETEC vaccine field remains sparsely populated. Emergent BioSolutions previously advanced an oral ETEC vaccine (ETVAX, developed with Scandinavian Biopharma) into Phase II/III trials, while Vaxart has explored oral tablet-based approaches. No candidate has reached licensure, and MecVax's polyvalent protein-based design — targeting both toxin and adhesin arms of ETEC pathogenesis in a single injectable subunit format — represents a distinct approach from oral live-attenuated or whole-cell killed platforms. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/etec-vaccine-grant-university-of-illinois)